UROGEN PHARMA LTD

UROGEN PHARMA LTD logo
🇮🇱Israel
Ownership
Public
Established
2004-01-01
Employees
201
Market Cap
-
Website
http://www.urogen.com

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

First Posted Date
2024-03-26
Last Posted Date
2024-08-19
Lead Sponsor
UroGen Pharma Ltd.
Target Recruit Count
87
Registration Number
NCT06331299
Locations
🇺🇸

Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States

🇺🇸

Urology Associates P.C. - Nashville, Nashville, Tennessee, United States

🇺🇸

Genesis Research, LLC, San Diego, California, United States

and more 2 locations

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

First Posted Date
2022-05-17
Last Posted Date
2024-04-18
Lead Sponsor
UroGen Pharma Ltd.
Target Recruit Count
60
Registration Number
NCT05375903
Locations
🇺🇸

Arkansas Urology, Little Rock, Arkansas, United States

🇺🇸

Manhattan Medical Research, New York, New York, United States

🇺🇸

Clinical Research Solutions, Middleburg Heights, Ohio, United States

and more 10 locations

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2022-02-17
Last Posted Date
2024-11-04
Lead Sponsor
UroGen Pharma Ltd.
Target Recruit Count
240
Registration Number
NCT05243550
Locations
🇦🇹

Medical University Vienna, Department of Urology, Vienna, Austria

🇪🇸

Hospital de Basurto, Bilbao, Spain

🇪🇸

Hospital del Mar, Barcelona, Spain

and more 62 locations

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)

First Posted Date
2021-11-30
Last Posted Date
2023-12-12
Lead Sponsor
UroGen Pharma Ltd.
Target Recruit Count
8
Registration Number
NCT05136898
Locations
🇺🇸

Medication Management, Greensboro, North Carolina, United States

🇺🇸

Urology Associates, P.C., Nashville, Tennessee, United States

🇺🇸

Virginia Urology, Richmond, Virginia, United States

and more 2 locations

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

First Posted Date
2020-12-30
Last Posted Date
2024-06-06
Lead Sponsor
UroGen Pharma Ltd.
Target Recruit Count
282
Registration Number
NCT04688931
Locations
🇺🇸

Stony Brook Cancer Center, Stony Brook, New York, United States

🇧🇬

Multiprofile Hospital for Active Treatment "Sveti Nikolai Chudotvorets", Lom, Lom, Bulgaria

🇺🇸

Urology Center, Las Vegas, Nevada, United States

and more 134 locations

Efficacy and Safety of UGN-101 in Recurrent Patients

First Posted Date
2019-07-05
Last Posted Date
2020-05-07
Lead Sponsor
UroGen Pharma Ltd.
Registration Number
NCT04006691
Locations
🇺🇸

Mayo Clinic Florida, Jacksonville, Florida, United States

🇺🇸

John Hopkins University, Baltimore, Maryland, United States

🇺🇸

UCLA - University of California, Los Angeles, Los Angeles, California, United States

and more 2 locations

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

First Posted Date
2018-06-15
Last Posted Date
2022-09-16
Lead Sponsor
UroGen Pharma Ltd.
Target Recruit Count
63
Registration Number
NCT03558503
Locations
🇺🇸

Loma Linda University, Loma Linda, California, United States

🇺🇸

Western New York Urology Associates, New York, New York, United States

🇺🇸

Providence Medical Institute, Santa Monica, California, United States

and more 16 locations

Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients

First Posted Date
2016-09-07
Last Posted Date
2016-09-08
Lead Sponsor
UroGen Pharma Ltd.
Target Recruit Count
18
Registration Number
NCT02891460
Locations
🇮🇳

Rajiv Gandhi Cancer Institute & Research Center, Delhi, New Delhi, India

© Copyright 2024. All Rights Reserved by MedPath